Chemoinformaics analysis of nomilinic-acid-glucoside
| Molecular Weight | 420.461 | nRot | 3 |
| Heavy Atom Molecular Weight | 396.269 | nRig | 8 |
| Exact Molecular Weight | 420.157 | nRing | 4 |
| Solubility: LogS | -3.598 | nHRing | 2 |
| Solubility: LogP | 3.437 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 3 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 55 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 31 | No. of Aromatic Carbocycles | 2 |
| nHetero | 6 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 24 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 25 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 16 |
| No. of Oxygen atom | 6 | No. of Arom Bond | 17 |
| nHA | 6 | APOL | 62.565 |
| nHD | 3 | BPOL | 28.417 |
| QED | 0.646 |
| Synth | 3.82 |
| Natural Product Likeliness | 2.55 |
| NR-PPAR-gamma | 0.004 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.991 |
| Pgp-sub | 0.01 |
| HIA | 0.006 |
| CACO-2 | -4.624 |
| MDCK | 0.0000163 |
| BBB | 0.252 |
| PPB | 0.942674 |
| VDSS | 1.293 |
| FU | 0.0681852 |
| CYP1A2-inh | 0.383 |
| CYP1A2-sub | 0.828 |
| CYP2c19-inh | 0.522 |
| CYP2c19-sub | 0.935 |
| CYP2c9-inh | 0.47 |
| CYP2c9-sub | 0.795 |
| CYP2d6-inh | 0.405 |
| CYP2d6-sub | 0.871 |
| CYP3a4-inh | 0.035 |
| CYP3a4-sub | 0.653 |
| CL | 1.007 |
| T12 | 0.799 |
| hERG | 0.012 |
| Ames | 0.012 |
| ROA | 0.025 |
| SkinSen | 0.941 |
| Carcinogencity | 0.743 |
| EI | 0.972 |
| Respiratory | 0.922 |
| NR-Aromatase | 0.003 |
| Antiviral | Yes |
| Prediction | 0.719894 |